1. Home
  2. AMCX vs ESPR Comparison

AMCX vs ESPR Comparison

Compare AMCX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMCX
  • ESPR
  • Stock Information
  • Founded
  • AMCX 1980
  • ESPR 2008
  • Country
  • AMCX United States
  • ESPR United States
  • Employees
  • AMCX N/A
  • ESPR N/A
  • Industry
  • AMCX Cable & Other Pay Television Services
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMCX Telecommunications
  • ESPR Health Care
  • Exchange
  • AMCX Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • AMCX 441.6M
  • ESPR 410.2M
  • IPO Year
  • AMCX 2011
  • ESPR 2013
  • Fundamental
  • Price
  • AMCX $7.71
  • ESPR $1.82
  • Analyst Decision
  • AMCX Hold
  • ESPR Buy
  • Analyst Count
  • AMCX 4
  • ESPR 6
  • Target Price
  • AMCX $8.75
  • ESPR $7.25
  • AVG Volume (30 Days)
  • AMCX 486.3K
  • ESPR 3.4M
  • Earning Date
  • AMCX 02-14-2025
  • ESPR 03-04-2025
  • Dividend Yield
  • AMCX N/A
  • ESPR N/A
  • EPS Growth
  • AMCX N/A
  • ESPR N/A
  • EPS
  • AMCX N/A
  • ESPR N/A
  • Revenue
  • AMCX $2,421,314,000.00
  • ESPR $295,451,000.00
  • Revenue This Year
  • AMCX $0.36
  • ESPR $186.86
  • Revenue Next Year
  • AMCX N/A
  • ESPR $9.41
  • P/E Ratio
  • AMCX N/A
  • ESPR N/A
  • Revenue Growth
  • AMCX N/A
  • ESPR 187.12
  • 52 Week Low
  • AMCX $7.08
  • ESPR $1.58
  • 52 Week High
  • AMCX $18.58
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • AMCX 29.06
  • ESPR 38.40
  • Support Level
  • AMCX $7.90
  • ESPR $1.82
  • Resistance Level
  • AMCX $9.91
  • ESPR $1.91
  • Average True Range (ATR)
  • AMCX 0.43
  • ESPR 0.09
  • MACD
  • AMCX -0.22
  • ESPR 0.02
  • Stochastic Oscillator
  • AMCX 0.00
  • ESPR 47.83

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached nearly 65 million pay-TV households in the US at the end of 2023. The firm also had nearly 11.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: